| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Dev. Op. Officer | Chief Dev. Op Officer | Chief Dev.op Officer +3 more
2 companies
Tanya Lewis is Chief Dev. Op. Officer at REPL, with reported holdings spanning 2 companies. Tanya Lewis's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $2.8M at current prices.
Our model assigns Tanya Lewis a middling insider score of 54/100, based on 3 past trades. Over a 12-month horizon, 66.7% of those trades were profitable, with an average 12-month return of +33.1%.
Tanya Lewis's largest disclosed position is in REPL as Chief Dev. Op. Officer, worth about $2.8M. The REPL filings lean toward selling, a net 30,540 shares.
Tanya Lewis has 18 Form 4 filings on record from February 2020 to June 2026, across 3 companies: Director at DiaMedica Therapeutics (DMAC), 2023–2026; Chief Dev. Op. Officer at Replimune Group (REPL), 2020–2023; EVP, Chief Reg. Affairs at Karyopharm Therapeutics (KPTI), 2020–2021.
The 25 reported transactions were 13 option or other derivative awards, 6 open-market sales, 4 stock awards and 2 option exercises.
Counted by filing, the open-market trades come to no purchases and 5 sales worth about $645K.
The largest open-market sale was 12,860 shares of REPL at an average $24.06 on June 13, 2023, about $309K. Twelve months later REPL was down 63%.
1 of the 2 sales since April 2023 was made under a Rule 10b5-1 trading plan; the other was not.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jun 13, 2023 | REPL Replimune Group, Inc. | Chief Dev. Op. Officer | Sell10b5-1 | 12,860 | $24.06 | $309,394.95 | -8.7% | -17.9% | -63.4% | |
| May 16, 2023 | REPL Replimune Group, Inc. | Chief Dev. Op. Officer | Sell | 12,207 | $18.05 | $220,336.35 | -7.6% | +6.5% | -63.2% | |
| May 16, 2022 | REPL Replimune Group, Inc. | Chief Dev. Op Officer | Sell | 5,473 | $14.59 | $79,851.07 | -4.3% | +42.1% | +27.3% | |
| Feb 11, 2021 | KPTI Karyopharm Therapeutics Inc. | EVP, Chief Reg. Affairs | Sell | 2,046 | $15.52 | $31,752.08 | -33.1% | - | - | |
| Oct 30, 2020 | KPTI Karyopharm Therapeutics Inc. | EVP,Chief Reg.& Quality Officer | Sale+OE | 226 | $15.58 | $3,521.08 | -29.5% | - | - |